KORU Medical Systems Past Earnings Performance
Past criteria checks 0/6
KORU Medical SystemsDie Erträge des Sektors -64.8% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Medical Equipment growing auf 9.1% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 8.4% pro Jahr gesunken.
Key information
-62.4%
Earnings growth rate
-62.0%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 7.9% |
| Return on equity | -67.5% |
| Net Margin | -48.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues
Feb 15
We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely
Sep 21Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower
Jul 14We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate
Sep 27Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans
Oct 27Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report
Aug 14Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?
Feb 22Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture
Jan 27KORU Medical Systems: A Razor & Razor Blade Story
Jan 11Is Repro Med Systems, Inc. (NASDAQ:KRMD) Trading At A 50% Discount?
Dec 29
Have Insiders Been Buying Repro Med Systems, Inc. (NASDAQ:KRMD) Shares This Year?
Dec 03The Independent Chairman of the Board of Repro Med Systems, Inc. (NASDAQ:KRMD), R. Fletcher, Just Bought 77% More Shares
Dec 03Repro Med Systems: Fair View Of The Fundamentals
Nov 18Repro Med Systems, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 05Repro Med Systems EPS misses by $0.01, misses on revenue
Nov 03Revenue & Expenses BreakdownBeta
How KORU Medical Systems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 29 | -14 | 20 | 6 |
| 30 Sep 23 | 29 | -8 | 19 | 6 |
| 30 Jun 23 | 29 | -8 | 20 | 6 |
| 31 Mar 23 | 29 | -9 | 20 | 5 |
| 31 Dec 22 | 28 | -9 | 21 | 5 |
| 30 Sep 22 | 27 | -8 | 21 | 4 |
| 30 Jun 22 | 25 | -8 | 20 | 4 |
| 31 Mar 22 | 24 | -6 | 18 | 3 |
| 31 Dec 21 | 23 | -5 | 18 | 2 |
| 30 Sep 21 | 21 | -4 | 16 | 2 |
| 30 Jun 21 | 21 | -3 | 15 | 1 |
| 31 Mar 21 | 23 | -3 | 14 | 1 |
| 31 Dec 20 | 24 | -1 | 12 | 1 |
| 30 Sep 20 | 26 | 0 | 12 | 1 |
| 30 Jun 20 | 27 | 0 | 11 | 1 |
| 31 Mar 20 | 25 | 1 | 10 | 1 |
| 31 Dec 19 | 23 | 1 | 10 | 1 |
| 30 Sep 19 | 21 | 0 | 10 | 1 |
| 30 Jun 19 | 19 | 0 | 9 | 0 |
| 31 Mar 19 | 18 | 0 | 9 | 0 |
| 31 Dec 18 | 17 | 1 | 8 | 0 |
| 30 Sep 18 | 18 | 2 | 8 | 0 |
| 30 Jun 18 | 17 | 2 | 8 | 0 |
| 31 Mar 18 | 16 | 1 | 8 | 0 |
| 31 Dec 17 | 16 | 1 | 8 | 0 |
| 28 Feb 17 | 12 | -1 | 8 | 0 |
| 30 Nov 16 | 13 | 0 | 7 | 0 |
| 31 Aug 16 | 13 | 0 | 7 | 0 |
| 31 May 16 | 13 | 1 | 6 | 0 |
| 29 Feb 16 | 12 | 1 | 6 | 0 |
| 30 Nov 15 | 12 | 1 | 6 | 0 |
| 31 Aug 15 | 12 | 1 | 5 | 0 |
| 31 May 15 | 11 | 1 | 5 | 0 |
| 28 Feb 15 | 11 | 1 | 5 | 0 |
| 30 Nov 14 | 10 | 1 | 4 | 0 |
| 31 Aug 14 | 10 | 1 | 4 | 0 |
| 31 May 14 | 9 | 1 | 4 | 0 |
| 28 Feb 14 | 9 | 1 | 4 | 0 |
| 30 Nov 13 | 8 | 1 | 4 | 0 |
| 31 Aug 13 | 8 | 0 | 4 | 0 |
| 31 May 13 | 8 | 1 | 4 | 0 |
Qualität der Erträge: KRMD ist derzeit unrentabel.
Wachsende Gewinnspanne: KRMD ist derzeit unrentabel.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: KRMD ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 64.8% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von KRMD verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: KRMD ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (3.7%) erschwert.
Return on Equity
Hohe Eigenkapitalrendite: KRMD hat eine negative Eigenkapitalrendite (-30.08%), da es derzeit unrentabel ist.